Willow Biosciences (TSX: WLLW) (OTCQB: CANSF), a Canadian biotechnology company creating high purity, plant-derived compounds for the global pharmaceutical, health and wellness and consumer packaged goods industries, today announced further acceleration of its path to commercialization following continued scale-up development success and the addition of multiple new cannabinoids for production. “Willow’s scientific and operational success to date has solidified the use of yeast fermentation as a production platform,” Willow’s CEO Trevor Peters stated in the news release. “Our scientific discoveries over the past 14 months have contributed to the development of not one, but five different cannabinoids and our pilot project production samples expected to be available in Q3 of 2020 will make Willow the first to biosynthetically produce material amounts of cannabinoids. We expect to offer a portfolio of ultra-pure, pharmaceutical grade quality cannabinoids by the end of 2021. As we transition from a research-focused company to a production company, we are investigating a variety of end markets, including pharmaceutical and consumer products. We see significant potential in consumer packaged goods for the North American recreation market, where interest for high quality ingredients such as ours is strong.”
To view the full press release, visit http://cnw.fm/zdfC9
About Willow Biosciences Inc.
Willow is a Canadian biotechnology company based in Calgary, Alberta, that produces high purity, plant-derived compounds that provide building blocks for the global pharmaceutical, health and wellness, and consumer packaged goods industries. Willow’s current focus is in the production of cannabinoids for the treatment for pain, anxiety, obesity, brain disorders, among other significant indications. Willow’s science team has a proven track record of developing manufacturing technologies for high purity compounds in pain and cancer treatments. Willow’s manufacturing process creates a consistent, scalable and sustainable product that allows for the discovery and development of new life changing drugs. For more information, visit the company’s website at www.WillowBio.com.
NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at http://cnw.fm/WLLW
CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CanadianCannabisWire.com
Do you have questions or are you interested in working with CNW? Ask our Editor